Dr. Matthew Meng Yang Lee graduated from the University of Edinburgh Medical School. He is a Cardiology Specialist Registrar in the West of Scotland and Clinical Lecturer at the School of Cardiovascular and Metabolic Health at the University of Glasgow. He was awarded the Bellahouston Medal for his PhD at the University of Glasgow, based on the SUGAR-DM-HF trial. His interests include clinical trials, heart failure, cardiomyopathies, obesity, diabetes, pharmacotherapy (SGLT2i, GLP-1RA, myosin inhibitors), meta-analyses, and multi-modality imaging (CMR, renal MRI, TTE, lung ultrasound). He is currently a CardioVascular Clinical Trialists (CVCT) Future Trialists Fellow. He serves on a trial steering committee (SEQUOIA-HCM) and clinical event committees (FINEARTS-HF, REVIVED-BCIS2, CABG-ACS).
Dr. Matthew Meng Yang Lee graduated from the University of Edinburgh Medical School. He is a Cardiology Specialist Registrar in the West of Scotland and Clinical Lecturer at the School of Cardiovascular and Metabolic Health at the University of Glasgow. He was awarded the Bellahouston Medal for his PhD at the University of Glasgow, based on the SUGAR-DM-HF trial. His interests include clinical trials, heart failure, cardiomyopathies, obesity, diabetes, pharmacotherapy (SGLT2i, GLP-1RA, myosin inhibitors), meta-analyses, and multi-modality imaging (CMR, renal MRI, TTE, lung ultrasound). He is currently a CardioVascular Clinical Trialists (CVCT) Future Trialists Fellow. He serves on a trial steering committee (SEQUOIA-HCM) and clinical event committees (FINEARTS-HF, REVIVED-BCIS2, CABG-ACS).